Kaposi's sarcoma

ROSALIND FRANKLIN UNIVERSITY GRANTS TO TACKLE COMPLICATIONS OF HIV AND STEM CELL THERAPY FOR BRAIN REPAIR

Retrieved on: 
Thursday, March 2, 2023
Knowledge, Aptamer, Cancer, Disease, Multimedia, Engineering, Biology, Myenteric plexus, Research, Regenerative medicine, Intelligence, KSHV, Patient, Facial muscles, Science, Infection, Neuroscience, Illinois Institute of Technology, B cell, PEL, Rosalind Franklin University of Medicine and Science, Primary effusion lymphoma, Tissue, National Cancer Institute, Culture, Kaposi's sarcoma, RFU, Microbiology, Neuron, IIT, Mortality, Cell, Chemical engineering, Brain, Vaccine

NORTH CHICAGO, Ill., March 2, 2023 /PRNewswire/ -- New funding for Rosalind Franklin University researchers will help revolutionize therapeutic approaches for HIV-related cancers and for brain repair.

Key Points: 
  • NORTH CHICAGO, Ill., March 2, 2023 /PRNewswire/ -- New funding for Rosalind Franklin University researchers will help revolutionize therapeutic approaches for HIV-related cancers and for brain repair.
  • "KSHV, a human oncogenic herpesvirus, is the underlying cause of KS tumor (lesions) and a rare B cell malignancy called primary effusion lymphoma (PEL)," Dr. Sharma-Walia said.
  • "KS is the most common vascular malignancy causing high morbidity and mortality in HIV-infected patients."
  • ROSALIND FRANKLIN UNIVERSITY encompasses six colleges and more than 10 research centers and institutes.

Spectrum Dermatology of Atlanta Welcomes Licensed Medical Aesthetician Danielle Lepori to the Practice

Retrieved on: 
Monday, February 27, 2023
Skin, Dermatology, MD, Laser, Kaposi's sarcoma, Carcinoma, Sclerotherapy, Patient, Skin care, Merkel-cell carcinoma, Woman, Hair, Health, Cosmetics

ALPHARETTA, Ga., Feb. 27, 2023 /PRNewswire-PRWeb/ -- At Spectrum Dermatology of Atlanta, Emma J. Murad, MD, and Susan R. Spitzler, MD, lead the team, providing state-of-the-art general and medical dermatological care. They are excited to announce that Danielle Lepori, a licensed medical aesthetician and laser practitioner, has joined the clinic. As a skin care specialist, Ms. Lepori is an expert on the latest techniques to enhance the skin's health and appearance and address a variety of skincare concerns. Danielle Lepori was born and raised in New York and has lived in Georgia for the past twenty years. She studied aesthetics and skincare at the renowned Paul Mitchel Esani Institute. Ms. Lepori brings to Spectrum Dermatology of Atlanta more than a decade of experience performing aesthetic treatments including facials, Hydrafacials, microneedling, and eyebrow microblading. She is a great addition to the well-rounded staff at Spectrum Dermatology and will provide the same attentive care and high-quality products to promote the best in comprehensive dermatological care for patients.

Key Points: 
  • They are excited to announce that Danielle Lepori, a licensed medical aesthetician and laser practitioner, has joined the clinic.
  • Ms. Lepori brings to Spectrum Dermatology of Atlanta more than a decade of experience performing aesthetic treatments including facials, Hydrafacials, microneedling , and eyebrow microblading.
  • Spectrum Dermatology of Atlanta offers the very latest in proven technologies and provides treatments for medical and cosmetic skin, nail and hair needs.
  • For more information about the services offered at Spectrum Dermatology of Atlanta or to schedule an appointment, please visit http://www.specdermatl.com or call (470) 731-8010.

Spectrum Dermatology of Atlanta is pleased to announce that Laney Hales, PA-C has Joined the Team

Retrieved on: 
Monday, February 20, 2023
Society, Skin, Woman, Medicine, Dermatology, Acne, Skin cancer, Patient, University, Kaposi's sarcoma, Carcinoma, Hair loss, Glycine mollis, Laser, Mercer University, Sclerotherapy, Hair, Merkel-cell carcinoma, Cyst, Rosacea, Longevity

ALPHARETTA, Ga., Feb. 20, 2023 /PRNewswire-PRWeb/ -- Spectrum Dermatology of Atlanta provides state-of-the-art general and medical dermatological care and offers exceptional quality in diagnosing and treating many conditions. From simple skin irritations to troubling hair loss, acne, cold sores, cysts, rosacea and skin cancer screenings and treatment, Dr. Murad and Dr. Spitzler and their team provide patients with compassionate care, advanced technology and effective treatment plans for a broad range of medical and cosmetic needs. This clinic is thrilled to welcome its new staff member, Laney Hales, PA-C. She makes a great addition to this extraordinary practice which is widely known for providing world-class care to patients. Ms. Hales is a Georgia native and received her undergraduate degree from the University of Georgia. She obtained her Master of Medical Science in physician assistant studies from Mercer University in Atlanta, GA. Laney Hales enjoys both the relational and hands-on aspects of dermatology. She is a diplomate fellow of the Society of Dermatology Physician Assistants, having completed additional training in dermatology. Her professional interests include longevity and anti-aging science and procedure-based treatment of skin disorders.

Key Points: 
  • ALPHARETTA, Ga., Feb. 20, 2023 /PRNewswire-PRWeb/ -- Spectrum Dermatology of Atlanta provides state-of-the-art general and medical dermatological care and offers exceptional quality in diagnosing and treating many conditions.
  • She is a diplomate fellow of the Society of Dermatology Physician Assistants, having completed additional training in dermatology.
  • Spectrum Dermatology of Atlanta offers the very latest in proven technologies and provides treatments for medical and cosmetic skin, nail and hair needs.
  • For more information about the services offered at Spectrum Dermatology of Atlanta or to schedule an appointment, please visit http://www.specdermatl.com or call (470) 731-8010.

Capstone Announces FDA Approval and EU Authorization of Doxorubicin Hydrochloride Liposome Injection

Retrieved on: 
Wednesday, December 14, 2022
Ovarian cancer, Food, Liposome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cardiomyopathy, Partnership, Royal commission, Cancer, Multiple myeloma, AIDS, Doxorubicin, FDA, European Commission, Kaposi's sarcoma, Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome (Prevention and Control) Act, 2017, Risk, Pharmaceutical industry, Extrusion, Medical device, Capstone, EU

ROSEMONT, Ill., Dec. 14, 2022 /PRNewswire/ -- Capstone Development Services Company LLC ("Capstone") announced today that it has received approval from the U.S. Food and Drug Administration (FDA), as well as authorization from the European Commission for doxorubicin hydrocholoride liposomal injection.

Key Points: 
  • ROSEMONT, Ill., Dec. 14, 2022 /PRNewswire/ -- Capstone Development Services Company LLC ("Capstone") announced today that it has received approval from the U.S. Food and Drug Administration (FDA), as well as authorization from the European Commission for doxorubicin hydrocholoride liposomal injection.
  • - Dan Robins, Ph.D., president, Capston
    Doxorubicin Hydrochloride Liposome Injectionisindicated for treatment of ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi's Sarcoma and multiple myeloma.
  • The authorizations mark the 19th and 20thth regulatory approvals Capstone has gained for products developed since its founding in 2013.
  • For more details about doxorubicin hydrocholoride liposomal injection, including the boxed warning for cardiomyopathy and infusion-related reactions, see full prescribing information.

TOOsonix announces granted patents for its non-invasive treatments of dermatological conditions

Retrieved on: 
Wednesday, November 9, 2022
Epidermis, Skin, Patent, Patient, Dermatology, Squamous cell carcinoma, IPR, A/S, Giant condyloma acuminatum, Dermis, Kaposi's sarcoma, Basal-cell carcinoma, Pectus carinatum, Foundation, Safety, Technology, CEO, Medical imaging, Pharmaceutical industry

HOERSHOLM, Denmark, Nov. 9, 2022 /PRNewswire/ -- TOOsonix A/S, a pioneer in high intensity focused ultrasound (HIFU) technology for dermatology, today announced that the United States Patent and Trademark Office (USPTO) has granted a U.S. patent no. 11/491,351 regarding its key technologies. The U.S. patent and already granted patents in Europe and China therefore complete the first phase of securing intellectual property rights for TOOsonix's unique technology in the major jurisdictions.

Key Points: 
  • The patents define methods for non-invasive and real-time image-guided treatment of skin using therapeutic ultrasound.
  • The technology has been implemented in the company's first product TOOsonix System ONE-M, which is currently in the late phase of approvals for medical treatments.
  • Torsten Bove and Tomasz Zawada, Co-founders of TOOsonix state: "Having patents in our three main markets has always been an essential milestone for the company.
  • TOOsonix is a Danish company pioneering therapeutic ultrasound for dermatological indications with its unique and patented high-frequency focused ultrasound device.

TOOsonix announces granted patents for its non-invasive treatments of dermatological conditions

Retrieved on: 
Wednesday, November 9, 2022
Epidermis, Skin, Patent, Patient, Dermatology, Squamous cell carcinoma, IPR, A/S, Giant condyloma acuminatum, Dermis, Kaposi's sarcoma, Basal-cell carcinoma, Pectus carinatum, Foundation, Safety, Technology, CEO, Medical imaging, Pharmaceutical industry

HOERSHOLM, Denmark, Nov. 9, 2022 /PRNewswire/ -- TOOsonix A/S, a pioneer in high intensity focused ultrasound (HIFU) technology for dermatology, today announced that the United States Patent and Trademark Office (USPTO) has granted a U.S. patent no. 11/491,351 regarding its key technologies. The U.S. patent and already granted patents in Europe and China therefore complete the first phase of securing intellectual property rights for TOOsonix's unique technology in the major jurisdictions.

Key Points: 
  • The patents define methods for non-invasive and real-time image-guided treatment of skin using therapeutic ultrasound.
  • The technology has been implemented in the company's first product TOOsonix System ONE-M, which is currently in the late phase of approvals for medical treatments.
  • Torsten Bove and Tomasz Zawada, Co-founders of TOOsonix state: "Having patents in our three main markets has always been an essential milestone for the company.
  • TOOsonix is a Danish company pioneering therapeutic ultrasound for dermatological indications with its unique and patented high-frequency focused ultrasound device.

US Kaposi's Sarcoma Market and Competitive Landscape - 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022
Health, Oncology, Epidemiology, Kaposi's sarcoma, Sarcoma, Competitive landscape, Research, Risk management, Pharmaceutical industry

The "US Kaposi's Sarcoma Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Kaposi's Sarcoma Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report US Kaposi's Sarcoma Market and Competitive Landscape Highlights - 2022, provides comprehensive insights into Kaposi's Sarcoma pipeline products, Kaposi's Sarcoma epidemiology, Kaposi's Sarcoma market valuations and forecast, Kaposi's Sarcoma drugs sales and competitive landscape in the US.
  • Kaposi's Sarcoma pipeline: Find out the products in clinical trials for the treatment of Kaposi's Sarcoma by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Kaposi's Sarcoma drugs: Identify key products marketed and prescribed for Kaposi's Sarcoma in the US, including trade name, molecule name, and company
    Kaposi's Sarcoma market valuations: Find out the market size for Kaposi's Sarcoma drugs in 2021 in the US.
  • Find out how the market advanced from 2019 and forecast to 2027
    Kaposi's Sarcoma drugs market share: Find out the market shares for key Kaposi's Sarcoma drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Kaposi's Sarcoma products

FIRST PATIENT WITH BASAL CELL CARCINOMA TREATED IN NEW FOCUSED ULTRASOUND STUDY: TOOsonix A/S

Retrieved on: 
Tuesday, April 19, 2022
Foundation, Documentation, PDT, Dermatology, Bispebjerg Hospital, Dyschromia, Epidermis, Dermis, Basal-cell carcinoma, Incidence, Hospital, Patient, University of Copenhagen, BCC, Trial of the century, HIFU, Temperature, Skin, Squamous cell carcinoma, Anesthetic, Comment, A/S, Kaposi's sarcoma, Physician, University, Risk, Cancer, Medical imaging, Bispebjerg

HOERSHOLM, Denmark, April 19, 2022 /PRNewswire/ -- TOOsonix A/S, a pioneer in high intensity focused ultrasound (HIFU) for dermatology, today announced that the first patients with basal cell carcinoma  have been treated in a new clinical study using its System ONE-M device.

Key Points: 
  • HOERSHOLM, Denmark, April 19, 2022 /PRNewswire/ --TOOsonix A/S, a pioneer in high intensity focused ultrasound (HIFU) for dermatology, today announced that the first patients with basal cell carcinoma have been treated in a new clinical study using its System ONE-M device.
  • The HIFU treatment will be administered as a single dosing of approximately 1-2 minutes of active focused ultrasound.
  • It can therefore directly and selectively treat areas affected by basal cell carcinoma, typically invading the outer layer of the human skin.
  • TOOsonix is a Danish company pioneering therapeutic ultrasound for dermatological indications with its unique and patented high-frequency focused ultrasound device.

FIRST PATIENT WITH BASAL CELL CARCINOMA TREATED IN NEW FOCUSED ULTRASOUND STUDY: TOOsonix A/S

Retrieved on: 
Tuesday, April 19, 2022
Foundation, Documentation, PDT, Dermatology, Bispebjerg Hospital, Dyschromia, Epidermis, Dermis, Basal-cell carcinoma, Incidence, Hospital, Patient, University of Copenhagen, BCC, Trial of the century, HIFU, Temperature, Skin, Squamous cell carcinoma, Anesthetic, Comment, A/S, Kaposi's sarcoma, Physician, University, Risk, Cancer, Medical imaging, Bispebjerg

HOERSHOLM, Denmark, April 19, 2022 /PRNewswire/ -- TOOsonix A/S, a pioneer in high intensity focused ultrasound (HIFU) for dermatology, today announced that the first patients with basal cell carcinoma  have been treated in a new clinical study using its System ONE-M device.

Key Points: 
  • HOERSHOLM, Denmark, April 19, 2022 /PRNewswire/ --TOOsonix A/S, a pioneer in high intensity focused ultrasound (HIFU) for dermatology, today announced that the first patients with basal cell carcinoma have been treated in a new clinical study using its System ONE-M device.
  • The HIFU treatment will be administered as a single dosing of approximately 1-2 minutes of active focused ultrasound.
  • It can therefore directly and selectively treat areas affected by basal cell carcinoma, typically invading the outer layer of the human skin.
  • TOOsonix is a Danish company pioneering therapeutic ultrasound for dermatological indications with its unique and patented high-frequency focused ultrasound device.

American Gene Technologies Advances Closer to Demonstrating a Potential Cure for HIV

Retrieved on: 
Thursday, February 24, 2022
Participation, Orphan, Cell, Physician, Population, Inherited disorders of trafficking, DSMB, PKU, Diagnosis, Immune system, University, Lead, Institutional review board, Clinical trial, Kaposi, University of California, San Francisco Fetal Treatment Center, Safety, Cancer, San Francisco AIDS Foundation, Person, IRB, Food, Maryland Department of Natural Resources, Kaposi's sarcoma, AGT, Infection, FDA, Maryland Department of Health, Patient, UNAIDS, Quality of life, Technology, Criticism of the Food and Drug Administration, ATI, ClinicalTrials.gov, Research, Republican Political Alliance for Integrity and Reform, HIV/AIDS, HIV, Pharmaceutical industry, Medical device, Vaccine, Phenylketonuria

The next logical step in the trial's progression: preparing to withdraw patients' antiretroviral therapy to potentially demonstrate a functional cure.

Key Points: 
  • The next logical step in the trial's progression: preparing to withdraw patients' antiretroviral therapy to potentially demonstrate a functional cure.
  • "The data we have already collected shows how close we could be to achieving our dream of curing HIV.
  • And, as we move forward, we are heartened to know that there are already tremendous HIV research findings and scientific value we've uncovered so far."
  • In the United States , government statistics show 1.2 million people have HIV and estimate that 34,800 Americans were newly infected with HIV in 2019.